Reproductive biotechnology company Memphasys (ASX: MEM) has received earlier than anticipated approval from the Thai Food and Drug Administration for its Felix system, clearing the final regulatory condition required to begin commercial sales under the company's exclusive three-year distribution agreement with IVF Envimed.

Felix is a benchtop device that uses electrophoresis to separate and isolate sperm based on size and charge characteristics, offering IVF laboratories an alternative to conventional centrifugation-based sperm preparation methods, which are more labour-intensive and time-consuming.

Following the Thai FDA approval, IVF Envimed has leveraged its well-established relationships with IVF clinics in Thailand to build early market interest in Felix. According to the company, positive clinic response has been driven by the potential clinical benefits of the system, including improved embryo utilisation and reduced sperm DNA fragmentation, together with its six-minute, simple and standardised sperm preparation process.

In response to this feedback and anticipated demand, IVF Envimed has placed an additional order for 100 Felix cartridges and three paid consoles, on top of the initial order of 100 cartridges and three consoles placed when the agreement was signed. IVF Envimed holds exclusive rights to sell and distribute the Felix system in Thailand under an agreement with a minimum contracted value of approximately $430,500 over three years.

Marjan Mikel, non-executive director and chair of the commercialisation committee, said that given the strong early interest generated by Envimed among Thai IVF clinics, Memphasys believes there is potential for Year 1 revenue to exceed the contracted minimum of $75,000, subject to the timing and level of customer demand.

"The early response to Felix from Thai IVF clinics has been extremely positive, and Envimed has responded by promptly ordering more Felix cartridges and consoles. That is exactly the commercial validation we want to see," Mr Mikel said. "We believe this is the start of a strong partnership with Envimed and, based on this early demand, we are confident of exceeding our Year 1 minimum contracted revenue."

Thailand is one of South-East Asia's largest assisted reproductive technology (ART) markets, conducting an estimated 20,000 to 30,000 IVF cycles annually across 110 registered IVF clinics nationwide. More than 95% of those cycles involve ICSI (intracytoplasmic sperm injection), which the company says underpins strong structural demand for advanced sperm selection devices such as Felix.

The Thai approval follows Memphasys' recent regulatory approval in Vietnam and advances the company's broader South-East Asian commercialisation strategy. The Thailand agreement and the company's two-year agreement with TMSC Viet Nam Medical Technology Company Limited carry a combined minimum contracted value of approximately A$1.0 million. The commencement of the Thai agreement expands Memphasys' growing international commercial network and provides a further pathway for converting contracted commitments into product supply and recurring cartridge sales. Because Felix generates ongoing revenue each time a console is used, the commercial model depends on clinics adopting the hardware and then consuming cartridges on a per-cycle basis.

Shares in MEM closed down 9.09% at 0.5 cents, giving the company a market capitalisation of $16.97 million.

Source: The Market Online